| Bioactivity | Pyronaridine is an orally active Mannich base anti-malarial agent. Pyronaridine is active against P. falciparum and Echinococcus granulosus infection[1][2]. |
| Invitro | Pyronaridine (24 h) shows anti-P. falciparum activity with an IC50 value of 1.53-3.94 nM[1]. |
| In Vivo | Pyronaridine (57 mg/kg, oral administration, q.d. for 30 days) reduces the parasitic burden in the Echinococcus granulosus-infected mice[2].Pyronaridine (57 mg/kg, intraperitoneal injection, q.d. for 3 days) reduces the parasitic burden in secondarily infected (cysts) mice[2].Pyronaridine (57 mg/kg, intraperitoneal injection, for a single dose) exhibits a higher exposure in the liver than in the plasma in male ICR mice[2]. Animal Model: |
| Name | Pyronaridine |
| CAS | 74847-35-1 |
| Formula | C29H32ClN5O2 |
| Molar Mass | 518.05 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Vivas L, et al. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop. 2008 Mar;105(3):222-8. [2]. Jun Li, et al. Old drug repurposing for neglected disease: Pyronaridine as a promising candidate for the treatment of Echinococcus granulosus infections. EBioMedicine. 2020 Apr;54:102711. |